Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need-Reference-Cited by-同舟云学术

Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need

Published:2023-08-18 Issue:1 Volume:8 Page:
ISSN:2059-0105
Container-title:npj Vaccines
language:en
Short-container-title:npj Vaccines

Author:

Cherian Neil^ORCID,Bettis Alison,Deol Arminder,Kumar Arun^ORCID,Di Fabio Jose Luis^ORCID,Chaudhari Amol^ORCID,Yimer Solomon,Fahim Raafat,Endy Timothy

Abstract

AbstractChikungunya is an arboviral disease caused by the chikungunya virus (CHIKV) afflicting tropical and sub-tropical countries worldwide. It has been identified as a priority pathogen by the Coalition for Epidemics Preparedness Innovations (CEPI) and as an emerging infectious disease (EID) necessitating further action as soon as possible by the World Health Organization (WHO). Recent studies suggest that disability-adjusted life years (DALYs) due to CHIKV infection are as high as 106,089 DALYs lost globally. Significant progress has been made in the development of several vaccines, aimed at preventing CHIKV infections. This perspective article summarizes CEPI’s efforts and strategic considerations for developing a CHIKV vaccine and ensuring equitable access for CHIKV endemic countries.

Funder

Coalition for Epidemics Preparedness Innovations

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology

Link

https://www.nature.com/articles/s41541-023-00722-x.pdf

Reference44 articles.

1. Valneva, S. E. Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate. Valneva.com. https://valneva.com/press-release/valneva-awarded-fda-fast-track-designation-for-chikungunya-vaccine-candidate/. https://valneva.com/wp-content/uploads/2019/06/2018_12_21_Chik_FDA__Fast_Track_PR_EN.pdf (2018).

2. Emergent Biosolutions. Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-ema-agreement-proposed (2020).

3. Schmidt, C. & Schnierle, B. S. Chikungunya Vaccine Candidates: Current Landscape. Drug Design, Development and Therapy (2022).

4. DeFilippis, V. R. Chikungunya Virus Vaccines: Platforms, Progress, and Challenges. Curr. Top. Microbiol. Immunol. vol. 435, pp 81–106 (2019).

5. Emergent Biosolutions. Press release. Emergentbiosolutions.com. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-department-defense-award-evaluate (2022).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection;Virulence;2024-01-13

2. [Short Communication] Immunology of a Morbillivirus: Measles 1954 to 2023;2023-11-23

3. [Short Communication] Immunology of a Morbillivirus: Measles 1954 to Current;2023-11-20

4. Programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysis;2023-09-26